California, USA-based Xoma Corp has filed an Investigational New Drug application with the US Food and Drug Administration for clinical testing of hu1124 in patients with moderate-to-severe psoriasis.
Previously referred to as anti-CD11a, hu1124 is a humanized monoclonal antibody that Xoma is developing in collaboration with Genentech for psoriasis and other indications, including organ transplant rejection. The planned trial will test the safety of the product in 30-40 psoriasis patients in multiple dosage groups. The filing comes less than five months from the start of the collaborative project and, says Genentech's executive vice president John McLaughlin, "confirms our opinion of Xoma's capability."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze